In this analysis of a prospective, multicenter study of children hospitalized with bronchiolitis, 925 had respiratory syncytial virus (RSV)-A and 649 had RSV-B. Overall, bronchiolitis severity did not differ by RSV subtype. However, among children with RSV-only bronchiolitis, those children with RSV-A had higher risk of intensive care treatment (odds ratio, 1.31; 95% confidence interval, 1.00-1.71; P = 0.048) when compared with those having RSV-B.
B
ronchiolitis is the leading cause of hospitalization in young children, and occurs commonly during the winter months due to respiratory viral infections. 1 Of the multiple viral etiologies, the most frequent is respiratory syncytial virus (RSV). Two antigenically different RSV subtypes exist, A and B. These 2 subtypes co-circulate during the same season, but in general, 1 predominates. 2 Although, some studies have shown that RSV-A is associated with an increased disease severity, [2] [3] [4] others have shown that either RSV-B is more severe 5 or that the 2 subtypes have equivalent severity. 6, 7 Most of these studies included 1 winter season or had small sample sizes, and in general used nonpolymerase chain reaction (PCR) diagnostics which in most may have omitted the confounding effects of viral coinfections or led to ascertainment bias. Therefore, our objective was to determine whether RSV subtype is independently associated with increased disease severity in a multicenter, multiyear sample of children hospitalized for bronchiolitis that utilized PCR diagnostics.
MATERIALS AND METHODS

Study Design
This is a secondary analysis of the 30th Multicenter Airway Research Collaboration prospective cohort study of children hospitalized with bronchiolitis. Study design and data collection would caspofungin. Like our patient, 2 adults received early antifungal prophylaxis (lung transplantation and an initial suspicion of aspergillosis). 7, 11 One patient was treated with itraconazole for 23 months and presented with pulmonary symptoms 17 months after stopping the prophylaxis and 5 months after corticosteroid pulses for acute rejection. 7 The other patient was treated with voriconazole and was asymptomatic at 5 months of follow-up. 11 The mechanism for the transmission of Coccidioides to recipients remains unclear but could be linked to a latent infection in the donated organs and the immunologic status of the recipient.
In conclusion, the case of this child highlights the point that coccidioidomycosis in recipients transplanted with organs from a suspected donor requires an exhaustive evaluation of the donor that includes serologic testing, chest imaging and, as in our case, PCR or mycologic culture at 25°C (up to 40°C on Sabouraud) of respiratory samples and in particular, whenever possible, histologic examination of the graft. 12 At present, primary donor-transmission prophylaxis with fluconazole (400 mg daily) or itraconazole (200 mg twice-daily) is recommended. If recipient lives in an endemic area, its duration should be adapted to the risk of de novo infection. 2, 12 If at risk for donor-derived coccidioidomycosis and receiving antifungal prophylaxis with echinocandin or inhaled aerosolized or oral amphotericin B, additional prophylaxis with an azole should be added. 12 The treatment undertaken for the patient may have not been the one recommended by guidelines, but they are American and adapted to the epidemiologic situation of the US. It seems that there are no similar guidelines for French or even European.
First-line therapy for coccidioidomycosis is fluconazole (400-800 mg daily). Intravenous amphotericin B (5 mg/kg/d) or voriconazole can be used in the event of severe infection or as salvage therapy, respectively. Lifelong secondary prophylaxis with fluconazole is also recommended. 12 methods have been previously described. 8 Briefly, during 3 winter seasons (November-March) from 2007 to 2010, up to 16 sites across 12 states enrolled children who were hospitalized with bronchiolitis, were <2 years of age, and for whom the parent/ guardian provided informed consent. Children were identified by daily census review and enrolled using a standardized protocol and treated at the discretion of the attending physician. The institutional review board at all participating hospitals approved the study.
Data Collection
Investigators conducted a structured interview that assessed patients' demographic characteristics, medical and environmental history, duration of symptoms and details of the acute illness. Medical records were reviewed to obtain clinical data from the preadmission evaluation and the child's inpatient course. Nasopharyngeal aspirates were collected using a standardized protocol and tested by PCR assays. Singleplex or duplex 2-step real time PCR (rtPCR) were used to detect RSV types A and B, rhinovirus, parainfluenza virus types 1, 2 and 3, influenza virus types A and B, 2009 novel H1N1, human metapneumovirus, coronaviruses (NL-63, HKU1, OC43 and 229E), enterovirus, adenovirus, Mycoplasma pneumoniae and Bordetella pertussis. 
Statistical Analyses
To compare demographic and clinical characteristics between the RSV subtypes, we performed unadjusted analyses using χ 2 , Fisher's exact test and Kruskall-Wallis test, as appropriate. Data are presented as proportions with 95% confidence intervals (95% CIs) and medians with interquartile ranges. We used multivariable logistic regression analyses to examine the independent association between RSV subtype and bronchiolitis severity outcomes. The primary outcome measure was hospital length of stay (LOS) ≥3 days (ie, an LOS greater than the cohort's median value of 2 days). 8 The secondary outcome measure was the need for intensive care treatment, defined as admission to the intensive care unit (ICU) and/or the use of mechanical ventilation [continuous positive airway pressure and/or intubation use] during the inpatient stay. During the study period, 1 site routinely provided continuous positive airway pressure outside of the ICU setting. The models adjusted for 11 patient characteristics (age, sex, race, ethnicity, maternal smoking during pregnancy, premature birth, history of wheeze, history of eczema, comorbid medical disorder, duration of difficulty breathing before preadmission and any coinfections) and patient clustering by site. In the sensitivity analysis models, we isolated RSV-A and B infections by excluding patients with RSV plus any another coinfections. Results were reported as odds ratios (ORs) with 95% CIs. All P values were 2 tailed, with P < 0.05 considered statistically significant. All analyses were performed using Stata 13.1 (Stata Corp, College Station, TX).
RESULTS
Among 2207 children hospitalized with bronchiolitis, 1589 (72%) tested positive for RSV. Of these, 925 (58%) had RSV-A, 649 (41%) had RSV-B and 15 (0.9%) had both RSV-A and RSV-B. To discretely compare RSV subtypes, we limited this analysis to the 1574 children with either RSV-A or RSV-B and excluded the 15 children infected with both subtypes.
The median age was 3.4 months (interquartile range, 1.5-7.2 months); 58% were male and 63% were white. When compared with those with RSV-B, children hospitalized with RSV-a bronchiolitis were more likely to be exposed in utero to tobacco (17% vs. 12%; P = 0.01) and to have pulse oximetry level <94% on admission (30% vs. 25%; P = 0.04). Detailed demographic characteristics and clinical course of the study population is included as Table, Overall, there was no significant association of RSV subtypes with severity outcomes-that is, LOS ≥3 days [adjusted odds ratio (OR), 0.92; 95% confidence interval (CI), 0.74-1.14; P = 0.45] and intensive care treatment (adjusted OR, 1.03; 95% CI, 0.85-1.24; P = 0.80). By contrast, in a sensitivity analysis restricted to RSV-only infections (ie, children infected only with RSV-A or RSV-B and no other viruses), children with RSV-A infection had an increased odds of receiving intensive care treatment (adjusted OR, 1.31; 95% CI, 1.00-1.71; P = 0.048) when compared with those with RSV-B (Table 1) .
DISCUSSION
In this multicenter, multiyear, prospective study of children hospitalized for bronchiolitis, we found that the severity of illness by RSV subtypes were similar. However, among children with RSV-only infections (ie, no coinfecting viruses), we found that children with RSV-A were more likely to require intensive care treatment compared with children with RSV-B, even after controlling for 11 other patient characteristics. Previous studies on RSV bronchiolitis in children have reported inconsistent associations of RSV subtype with severity of illness. In studying 81 hospitalized infants with bronchiolitis, Fodha et al 7 showed no independent association between RSV subtype (determined by PCR) and increased disease severity. On the contrary, Papadopoulos et al 4 observed a small but statistically significant difference of increased disease severity caused by RSV-A, as determined by a composite clinical score index. However, 41% of the specimens could not be subtyped by rtPCR, and the study was limited to a single winter season. Walsh et al 2 also demonstrated an increased severity index by RSV-A infection in a 3-year prospective study of 265 infants with RSV infection (51% had RSV-A). The increased severity index was driven by differences in hypercarbia, apnea and need for mechanical ventilation. 2 In contrast, our study did not detect significant differences in apnea or need for mechanical ventilation, but for ICU admission, one of the measures of disease severity (Table 1) . We did not include arterial CO 2 in the analysis because it was rarely performed outside of the ICU setting or without the use of some form of advanced respiratory support. Multivariable analysis limited to those patients with sole RSV infection (ie, no coinfections) showed that children with RSV-A infection had 1.31 higher odds of requiring intensive care treatment, although LOS ≥3 days was not different between the subtypes. This is noteworthy, because RSV subtypes were not identified at the participating hospitals during the study period and therefore, the RSV subtype would not have influenced the clinical decision to admit a child to the ICU and/or to provide mechanical ventilation. One way to reconcile the discrepant findings of the aforementioned studies is by recognizing that the outcomes of RSV subtype-specific bronchiolitis can be affected by the presence of viral coinfections; and that by analyzing RSV-only infections, the true biologic effect can be ascertained. In this sense, our results would suggest that the peak severity of illness may be higher with RSV-A, without affecting the LOS.
Major strengths of this study include the prospective and standardized data collection, the large sample size (n = 1574), and the case ascertainment method by rtPCR. Attending physicians were blinded to the virus subtype, as testing took place after each study season. Finally, we believe the results should be generalizable to other geographic areas beyond the United States with similar therapeutic approach to severe bronchiolitis.
The study has several potential limitations. First, only hospitalized children were enrolled in this study, so results may not be generalizable to outpatients. However, our inferences are of direct relevance to hundreds of thousands of children with severe bronchiolitis every year. Second, we did not examine the association between viral genomic load and disease severity or the variability in the genetic composition of circulating strains, which may have conferred increased viral pathogenicity, if subjects had no preexisting antibodies. Finally, we did not use standard criteria for hospital discharge or intensive care use; therefore, institutional variability in care is possible. However, the significant associations persisted after accounting for clustering at the hospital level.
CONCLUSIONS
This large, prospective, multicenter, multiyear US study of hospitalized children with bronchiolitis showed no difference in clinical severity between children with RSV-A and RSV-B. However, when we restricted the analysis to children with RSV-only infections, by excluding coinfections, we found that RSV-A had a modest, yet significant association with higher severity of illness. Subtype B was the prevalent circulating type during January for the 3 consecutive winter seasons. These findings suggest that preventive interventions (active or passive immunoprophylaxis) and antiviral therapies will be more beneficial for children if they are equally effective against both RSV subtypes.
